| Name | Title | Contact Details |
|---|
RuiYi is focused on the discovery and development of novel biologic therapeutics that have the potential to be disruptive globally. In addition to RYI-018 and RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company's technologies, including the iCAPS (intramembranous Conformation Antigen Presenting System). Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators. RuiYi's executive management team has offices in La Jolla, California, and RuiYi's discovery efforts and research facility are located in in the Zhangjiang Hi-Tech Park in Pudong, Shanghai, China.
Adrian Elwell at Au Top is a Danville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tempest Therapeutics is a development-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways.
Response Biomedical Corporation is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Phycotransgenics is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.